news

COVID-19 Drug Repurposing Database made open-access by Excelra

The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.

drug capsule repelling coronavirus particles

Excelra has announced the release of its open-access COVID-19 Drug Repurposing Database to help in the search for a therapeutic to combat the SARS-CoV-2 coronavirus, causing the global pandemic.

The database contains a compilation of previously approved small molecules and biologics with known pre-clinical, pharmacokinetic, pharmacodynamic and toxicity profiles that can rapidly enter either Phase II or III clinical trials on fast track basis for COVID-19. The resource also includes information on promising COVID-19 drug candidates at all stages of drug discovery and development.

Dr Nandu Gattu, Senior Vice President of Pharma Analytics at Excelra, said: “The COVID-19 Drug Repurposing Database is a compilation of crucial data that is dispersed across numerous publications, reports, databases and knowledge-repositories along with referenced literature covering the drug, disease, target and mechanism of action. Our endeavour is in support to the ongoing global scientific efforts for identifying safe and effective therapeutic options to treat the novel coronavirus disease.” 

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

The company’s drug repurposing database is powered by its Global Repurposing Integrated Platform (GRIP) which combines proprietary repurposing databases, algorithms, analytics tools and a visualisation engine. The GRIP database is built by amassing vast chemical data, biological data and clinical data.